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Objectives—To determine whether contrast-enhanced sonographic quantitative
perfusion parameters can detect bowel wall fibrosis in the setting of mixed inflam-
matory and fibrotic lesions in a Crohn disease animal model.
Methods—This study was approved by the institutional Committee on the Use and
Care of Animals. Multiple (range, 1–5) 2,4,6-trinitrobenzenesulfonic acid–ethanol
enemas were used to create intestinal inflammatory lesions with variable fibrosis in
female Lewis rats. Low–mechanical index contrast-enhanced sonography was per-
formed 3 days after the final enema using a 0.2-mL bolus of sulfur hexafluoride
microbubbles injected through a tail vein. Contrast-enhanced sonographic data were
analyzed with software that converts video data into echo-power (linearized) data.
Colorectal lesions were scored for histopathologic inflammation and fibrosis; bowel
wall collagen was quantified by Western blotting. The Spearman correlation was
used to assess associations between contrast-enhanced sonographic quantitative
parameters and bowel wall collagen; the Kruskal-Wallis test was used to compare
continuous results between histopathologic groups.
Results—Thirty-one animals were included in our analysis. Animals were placed
into 3 histopathologic cohorts: (1) severe bowel wall inflammation/minimal or no
fibrosis (n5 11); (2) severe bowel wall inflammation/moderate fibrosis (n5 9);
and (3) severe bowel wall inflammation/severe fibrosis (n5 11). Western blotting
showed a significant difference in bowel wall collagen between histopathologic
cohorts (P5 .0001). There was no correlation between any contrast-enhanced
sonographic quantitative parameter and bowel wall collagen (P> .05). There was
no difference between histopathologic cohorts for any contrast-enhanced sono-
graphic quantitative parameter (P> .05).
Conclusions—Contrast-enhanced sonographic quantitative perfusion parameters
failed to effectively detect bowel wall fibrosis in the setting of superimposed inflam-
mation in a Crohn disease animal model.
Key Words—animal model; contrast-enhanced sonography; Crohn disease;
gastrointestinal ultrasound; fibrosis; inflammation; microbubble contrast agent
C rohn disease is a chronic inflammatory condition that affectsthe human gastrointestinal tracts of both children and adultsand is due to immune system dysregulation.1,2 Patients with
this disorder commonly have periods of disease exacerbation due to
worsening intestinal inflammation. In some patients, however, an
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exacerbation of symptoms may be due to the presence
of a stricture.3 Strictures are segments of narrowed
bowel lumen with variable degrees of obstruction that
are most often due to a combination of both inflamma-
tion and fibrosis.4 Pathologic bowel wall fibrosis is the
result of aberrant healing secondary to recurrent bouts
of intestinal inflammation and associated damage.3 The
detection of bowel wall fibrosis is paramount, as areas
of intestinal narrowing that are primary inflammatory
may be sufficiently managed with medical (eg, anti-
inflammatory or immunosuppressive) therapy, whereas
strictures containing considerable fibrosis require
mechanical treatments, such as intestinal resection,
stricturoplasty, or endoscopic balloon dilation.3,5
Unfortunately, the detection and measurement of
intestinal fibrosis using conventional radiologic tests is
difficult. A study by Adler et al6 showed that whereas
computed tomography can effectively detect active
bowel wall inflammation, it performs suboptimally when
trying to predict intestinal fibrosis. Although magnetic
resonance imaging offers greater soft tissue contrast
resolution compared to computed tomography, recent
studies suggest that this modality can only effectively
detect severe transmural intestinal fibrosis based on the
presence of delayed contrast enhancement7 or substan-
tial luminal dilatation proximal to an area of narrowing.8
A few small preliminary studies have assessed a vari-
ety of ultrasound technologies for the detection of bowel
wall fibrosis in the setting of Crohn disease. Kim et al9
and Stidham et al10 showed that ultrasound strain elas-
tography can be used to detect bowel wall fibrosis in a
Crohn disease rodent model, whereas Dillman et al11,12
showed that ultrasound shear wave elastography may be
useful for detecting bowel wall fibrosis in both rodents
and ex vivo human Crohn disease specimens. A small
number of investigators have attempted to use contrast-
enhanced sonography to detect fibrosis in human Crohn
disease strictures. Nylund et al13 concluded that fibrotic
strictures were associated with reduced blood flow and
blood volume based on contrast-enhanced sonographic
assessment. Quaia et al14 also concluded that fibrotic
strictures could be differentiated from inflamed bowel
segments based on contrast-enhanced sonographic time-
versus-signal intensity areas under the curve.
The purpose of our study was to further evaluate
the ability of contrast-enhanced sonography using an
intravascular microbubble contrast agent to detect the
presence of intestinal fibrosis in a Crohn disease animal
model. Specifically, we wanted to determine whether a
variety of contrast-enhanced sonographic quantitative
perfusion parameters derived from time-versus-signal
intensity curves can be used to detect the presence of
bowel wall fibrosis in mixed inflammatory and fibrotic
lesions.
Materials and Methods
This investigation was approved by the institutional
Committee on the Use and Care of Animals. The previ-
ously described 2,4,6-trinitrobenzenesulfonic acid
(TNBS)–ethanol enema Crohn disease rat model was
used to create intestinal inflammatory lesions with vari-
able amounts of bowel wall fibrosis.15,16 In this chemi-
cally induced colitis model, ethanol is used to disrupt the
integrity of the mucosa of the distal colon and rectum,
whereas TNBS serves as a hapten, producing a vigorous
immunologic inflammatory reaction in the bowel wall
consisting of neutrophils, lymphocytes, activated mast
cells, macrophages, and fibroblasts. A single TNBS-
ethanol enema causes acute colorectal inflammation that
peaks in 2 to 3 days and resolves in about 1 week. Repet-
itive weekly TNBS-ethanol treatments cause repeated
cycles of intestinal inflammation and healing that effec-
tively produce acute-on-chronic inflammation and trans-
mural bowel wall fibrosis in 4 to 6 weeks in a manner
similar to human Crohn disease.9,11
Thirty-six female Lewis rats were divided into 5
groups. Group 1 animals (n5 12) received a single
TNBS-ethanol enema in an attempt to create colorectal
inflammatory lesions without fibrosis; these animals
underwent contrast-enhanced sonography 3 days after
the enema procedure. Group 2, 3, 4, and 5 animals
(n5 6, respectively) received 2, 3, 4, and 5 weekly ene-
mas, respectively, in an attempt to create intestinal
inflammatory lesions with variable amounts of associated
bowel wall fibrosis. Again, contrast-enhanced sonogra-
phy was performed 3 days after the final enema. Group
5 animals were expected to develop intestinal inflamma-
tory lesions with associated severe transmural fibrosis.
All enemas were delivered through a 5-F pediatric feed-
ing tube while the animals were transiently anesthetized
with inhaled isoflurane.
Low–mechanical index (0.08) contrast-enhanced
sonography was performed with Cadence contrast pulse
sequencing technology (Acuson 3000 ultrasound system
and 9L4 linear high-frequency transducer; Siemens
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Medical Solutions USA, Inc, Mountain View, CA) and a
sulfur hexafluoride microbubble contrast agent (SonoVue;
Bracco Diagnostics, Inc, Milan, Italy) injected through a
peripheral 24-gauge catheter placed within a lateral tail
vein. Contrast-enhanced sonography using Cadence con-
trast pulse sequencing allows the detection of strong non-
linear fundamental and high-order harmonic signals that
are predominantly from the intravascular contrast agent.17
The microbubble contrast agent was hand injected by
“bolus” technique and a 1-mL syringe, with 0.2 mL of the
contrast agent injected over 1 second, followed immedi-
ately by a 0.5 mL of a normal saline flush injected over 5
seconds. Sixty-second video clips were recorded in the
area of greatest colorectal wall thickening as depicted by
grayscale sonography (Figure 1), starting at the initiation
of contrast agent injection. Contrast-enhanced sonogra-
phy was performed in the transverse plane (Figure 2).
Digital Imaging and Communications in Medicine
contrast-enhanced sonographic video clips were ana-
lyzed with VueBOX version 6.0 software (Bracco Suisse
SA, Plan-les-Ouates, Switzerland). This software package
converts Digital Imaging and Communications in Medi-
cine video data into echo-power (linearized) data, a
quantity that is directly proportional to the instantane-
ous concentration of the contrast agent at each location
Figure 1. A, Appearance of a euthanized rat abdomen after a single
TNBS-ethanol enema. The cecum (Ce) appears normal, whereas the
descending colon (Co) is thick-walled and inflamed. The colon
appears very erythematous between the arrows. L indicates liver. B,
Transverse grayscale sonogram the rat pelvis showing marked wall
thickening of the rectosigmoid colon (arrows) due to a combination
of inflammation and fibrosis. Echogenic shadowing material in the
bowel lumen is fecal material.The anechoic fluid-filled structure to the
left of the colon is the urinary bladder.
Figure 2. A, Grayscale and contrast-specific sonograms through an
abnormal rat colon immediately after contrast agent injection and
before bowel wall enhancement.Contrast material is present in a large
pelvic vein (arrows). B, Grayscale and contrast-specific images a few
seconds later showing avid enhancement of the bowel wall (arrows).
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on the image. Numerous quantitative perfusion parame-
ters (time [seconds], amplitude [arbitrary units], rate
[arbitrary units], and area under the curve [arbitrary
units] based) were generated from sonographic time-
versus-signal intensity (enhancement) curves to provide
estimates of local perfusion, as shown in Figure 3. All
video clips were processed by a single author. For each
contrast-enhanced sonographic clip, a region of interest
was placed within the anterior wall (from approximately
the 9- to 10- to 2- to 3-o’clock locations) of the bowel
segment of interest, extending from the inner mucosa
to the outer serosa (Figure 4). Color parametric maps
for contrast-enhanced sonographic quantitative perfu-
sion parameters also were generated, as also shown in
Figure 4.
Colorectal Histologic Scoring
After contrast-enhanced sonography, animals were imme-
diately euthanized, and colorectal tissues were dissected
free. Full-thickness bowel wall tissue was sampled from
the area of greatest colorectal wall thickening and proc-
essed by standard histologic methods. A board-certified
gastrointestinal pathologist reviewed hematoxylin-eosin–
as well as Masson trichrome–stained slides to document
the amounts of bowel wall histopathologic inflammation
and fibrosis using Likert-like scales (Table 1), while
blinded to the contrast-enhanced sonographic results.
Animals were then placed into new cohorts for our final
analyses based on histopathologic scoring.
Bowel wall collagen protein was isolated from the
sampled bowel wall specimens, quantified by Western
blotting using a rabbit polyclonal antibody against type I
collagen (Rockland, Gilbertsville, PA), and normalized
to glyceraldehyde-3-phosphate dehydrogenase.10 Auto-
radiographs were digitally scanned and quantified with
ImageJ analysis software.18
Statistical Analysis
As the number of animals in each histopathologic
cohort was relatively small, medians were used to sum-
marize continuous data, and nonparametric statistical
testing was performed. The Spearman rank correlation
was used to assess the relationships between contrast-
enhanced sonographic quantitative parameters and
bowel wall collagen. The Kruskal-Wallis test (nonpara-
metric version of analysis of variance) was used to
Figure 3. A, Schematic of a time-versus-signal intensity curve using the bolus contrast-enhanced sonographic technique. Numerous quantitative
parameters can be derived from this curve. FT indicates fall time; mTTl, mean local transit time; PE, peak enhancement; RT, rise time; TTP, time to
peak; WiAUC, wash-in area under the curve; WiR, wash-in rate; WiWoAUC, wash-in1wash-out area under the curve; WoAUC, wash-out area
under the curve; and WoR, wash-out rate. Modified from http://vuebox.bracco.ch/. B, Time-versus-signal intensity curve from a distal rat colon
showing a linearized signal and fitted curve (solid green line); a.u. indicates arbitrary units.
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compare continuous data (medians) between 3 or
more groups. Pair-wise comparisons were performed
using the Dunn multiple-comparisons test. P< .05 was
considered statistically significant for all inference test-
ing. Statistical analysis was performed with Prism 6 soft-
ware (GraphPad Software, Inc, La Jolla, CA).
As our study was small and pilot in nature, we chose
not to adjust our significance level (a) to account for
the multiplicity of contrast-enhanced sonographic quan-
titative parameters assessed. An a priori power calcula-
tion showed that we had at least 80% power to detect a
correlation of 0.5 or greater between contrast-enhanced
Figure 4. Contrast-enhanced sonographically derived quantitative parameters can be expressed as color parametric maps. A, Peak
enhancement. B, Wash-in area under the curve.C, Combined wash-in and wash-out area under the curve.D, Time to peak enhancement.
Table 1. Histologic Grading of Bowel Wall Inflammation and Fibrosis
Score Description
Inflammation
0 No inflammation
1 (mild) Few neutrophils in mucosa/submucosa; no transmural injury or necrosis
2 (moderate) Many neutrophils in mucosa/submucosa; no transmural injury or necrosis
3 (severe) Neutrophils in all layers of bowel wall; transmural injury or necrosis
Fibrosis
0 No architectural distortion; negative Masson trichrome staining
1 (mild) No architectural distortion; positive Masson trichrome staining in <50% bowel wall
2 (moderate) No architectural distortion; positive Masson trichrome staining in >50% bowel wall
3 (severe) Architectural distortion of muscularis propria; positive Masson trichrome staining in all layers of bowel wall
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sonographic quantitative parameters and bowel wall col-
lagen. Any statistically significant correlation of less than
0.5 that we might have been underpowered to detect
was thought to be unlikely to be clinically important.
Results
Thirty-one animals were included in our final analysis,
which yielded diagnostic contrast-enhanced sonographic
time-versus-signal intensity data (VueBOX quality of fit,
>90%). Five animals were excluded from the analysis
because of nondiagnostic contrast-enhanced sono-
graphic video clips; these animals had considerable intes-
tinal peristalsis, which resulted in poor curve fitting to
the linearized sonographic data and, thus, likely inaccu-
rate estimates of contrast-enhanced sonographic quanti-
tative perfusion parameters.
Bowel Wall Histopathologic Scoring and Collagen
Content
After histopathologic assessment of sampled colorectal
tissues, animals were placed into 3 cohorts: a cohort
with severe transmural bowel wall inflammation
(inflammation score of 3) and minimal fibrosis (fibrosis
score of 0 or 1; n5 11); a cohort with severe trans-
mural bowel wall inflammation (inflammation score of
3) and moderate fibrosis (fibrosis score of 2; n5 9);
and a cohort with severe transmural bowel wall inflam-
mation (inflammation score of 3) and severe trans-
mural fibrosis (fibrosis score of 3; n5 11). The
Western blot analysis revealed a significant difference in
median normalized bowel wall collagen between histo-
pathologic cohorts (cohorts 1 versus 2 versus 3: 0.005
versus 0.43 versus 0.23; P5 .0001). There were signifi-
cant differences in bowel wall collagen between cohorts
1 and 2 (P5 .0005) and cohorts 1 and 3 (P5 .0008)
but not between cohorts 2 and 3 (P> .99).
Correlation Between Contrast-Enhanced Sonographic
Quantitative Perfusion Parameters Versus Bowel
Wall Collagen
Spearman rank correlation was used to assess the rela-
tionship between the numerous contrast-enhanced
sonographic quantitative perfusion parameters evaluated
and bowel wall collagen. No statistically significant corre-
lation was identified. Correlation coefficients and P val-
ues are presented in Table 2.
Contrast-Enhanced Sonographic Quantitative
Perfusion Parameters Versus Histopathologic Cohort
The Kruskal-Wallis test was used to compare contrast-
enhanced sonographic quantitative perfusion parameter
medians for each histopathologic cohort. No significant
difference was identified between cohorts for any param-
eter. Medians and P values are presented in Table 3.
Discussion
Although numerous studies have demonstrated that
contrast-enhanced sonography can be used to identify
and quantify bowel wall inflammation in the setting of
Crohn disease,19–21 our results suggest that contrast-
enhanced sonographic quantitative perfusion parameters
cannot effectively detect the presence of bowel wall
Table 2. Correlation Between Contrast-Enhanced Sonographic
Quantitative Perfusion Parameters and Bowel Wall Collagen
Parameter qa Pa
Peak enhancement, a.u. 0.10 .62
Wash-in AUC, a.u. 0.05 .80
Rise time, s 20.33 .08
Mean transit time, s 20.17 .39
Time to peak, s 20.36 .06
Wash-in rate, a.u. 0.19 .33
Wash-in perfusion index, a.u. 0.11 .57
Wash-out AUC, a.u. 20.03 .86
Wash-in1wash-out AUC, a.u. 20.01 .96
Fall time, s 20.28 .15
Wash-out rate, a.u. 0.22 .25
AUC indicates area under the curve; and a.u., arbitrary units.
aSpearman rank correlation.
Table 3. Contrast-Enhanced Sonographic Quantitative Perfusion
Parameter Medians by Histopathologic Cohort
Parameter
Cohort 1
(n5 11)
Cohort 2
(n5 9)
Cohort 3
(n5 11) Pa
Peak enhancement, a.u. 61.8 117.0 119.6 .34
Wash-in AUC, a.u. 128.0 169.5 130.1 .31
Rise time, s 2.9 1.8 1.9 .07
Mean transit time, s 12.1 11.5 8.9 .09
Time to peak, s 3.7 2.6 2.8 .07
Wash-in rate, a.u. 29.8 71.0 94.0 .20
Wash-in perfusion
index, a.u.
40.4 77.1 75.5 .28
Wash-out AUC, a.u. 364.4 512.1 266.2 .09
Wash-in1wash-out
AUC, a.u.
513.7 681.5 374.1 .13
Fall time, s 8.7 4.5 4.2 .07
Wash-out rate, a.u. 7.2 16.8 30.4 .16
AUC indicates area under the curve; and a.u., arbitrary units.
aKruskal-Wallis test.
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fibrosis when considerable intestinal inflammation is also
present. This key limitation is important to recognize, as
human Crohn disease strictures can be histopathologically
mixed, containing both inflammation and fibrosis.7–9
Unfortunately, this particular clinical setting (histopatho-
logically mixed strictures) is common and may represent
most resected Crohn disease strictures in both children
and adults based on these recent publications.
Microbubble contrast agents used for contrast-
enhanced sonography remain strictly intravascular and do
not have an extravascular (or interstitial) phase. There-
fore, the degree and pattern of bowel wall enhancement
observed on contrast-enhanced sonography are princi-
pally perfusion related. Accordingly, it is likely that in the
setting of mixed inflammatory and fibrotic Crohn disease
lesions, contrast-enhanced sonographic quantitative
perfusion parameters are predominantly influenced by
the amount of bowel wall inflammation, regardless of
the amount of superimposed fibrosis. This situation is
different than with intravenously administered iodin-
ated contrast agents used for computed tomographic
enterography and conventional linear and macrocyclic
gadolinium chelates used for magnetic resonance enter-
ography, which have both intravascular and extravascu-
lar phases. Although early bowel wall enhancement is
driven by perfusion and the amount of the intravascular
contrast agent for these particular contrast materials,
the contrast agent also can enter the interstitium of the
bowel wall over time and accumulate/wash-out at dif-
ferent rates based on the presence of fibrosis, as docu-
mented by Rimola et al.7
Our results are in contradistinction to 2 prior studies
that assessed contrast-enhanced sonography in human
patients with Crohn disease. Nylund et al13 concluded
that fibrotic strictures were associated with reduced
blood flow and blood volume based on contrast-
enhanced sonographic assessment, whereas Quaia et al14
concluded that fibrotic strictures could be differentiated
from inflamed bowel segments based on contrast-
enhanced sonographic time-versus-signal intensity areas
under the curve. However, a review of the methods used
by Nylund et al13 showed that surgically resected intes-
tine was available for histopathologic assessment and to
serve as a reference standard for only about half of their
patients. Additionally, whereas resected bowel specimens
were scored for the amount of histopathologic bowel
wall fibrosis, there was no specific mention of histopatho-
logic scoring of inflammation or how many resected
fibrotic strictures had superimposed inflammation (and
to what degree). The reference standard in the study by
Quaia et al14 was endoscopic deep mucosal biopsy,
which provides a limited assessment of the bowel wall, as
it fails to reflect the status of most of the bowl wall depth
with regard to inflammation and fibrosis. In their study,
they classified patients into 2 discrete categories: those
with inflammatory strictures and those with fibrotic stric-
tures. Their study failed to account for the possibility of
mixed lesions containing both inflammation and fibrosis,
which again appear to be quite common on the basis of
recent reports.
Our study had limitations. First, it was performed in
a Crohn disease animal model as opposed to human
patients with Crohn disease. However, this model can
be considered advantageous in some ways, and it allows
reproducible scientific methods and effective access to
full-thickness bowel wall histopathologic findings as a
reference standard to compare our contrast-enhanced
sonographic results against. Second, all colorectal lesions
that were created by the TNBS-ethanol enema model
contained severe transmural inflammation; we did not
specifically assess the ability of contrast-enhanced sonog-
raphy to detect fibrosis in the absence of inflammation.
Again, such strictures seem to be uncommon according
to recently published reports. Finally, the number of ani-
mals used in our study was relatively small. When per-
forming animal studies and determining the animals to
be subjected to experimentation, it is important to bal-
ance the ability to detect a statistically significant result
with what would be a clinically relevant result as well as
with ethical concerns. On the basis of our results, we
believe that our study contained a sufficient number of
animals to support our conclusions.
In conclusion, contrast-enhanced sonographic quan-
titative perfusion parameters failed to reliably detect
bowel wall fibrosis in the setting of superimposed
inflammation in a Crohn disease animal model. Like-
wise, there was no significant correlation between any
contrast-enhanced sonographic quantitative perfusion
parameter and the amount of bowel wall collagen, as
determined by the Western blot technique. It is very
likely that these parameters are primarily influenced by
bowel wall inflammation, as microbubble contrast agents
are confined to the intravascular compartment. Our
results bring into question the ability of contrast-
enhanced sonography to detect and quantify bowel wall
fibrosis most human Crohn disease strictures, which
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commonly contain both substantial inflammation and
fibrosis.
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